Improvement of motor fluctuations in patients with parkinson’s disease following treatment with high doses of pergolide and cessation of levodopa

European Neurology

Volumn 37, Issue 4, 1997, Pages 236-238

  Schwarz, Johannes ^a   Scheidtmann, Klaus ^b   Trenkwalder, Claudia ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Dopamine agonist; Levodopa; Motor fluctuations; Parkinson s disease; Pergolide

Indexed keywords

AMANTADINE; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE;

ADULT; AGED; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKINESIA; MALE; MOTOR PERFORMANCE; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PERGOLIDE;

EID: 0030969190     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000117449     Document Type: Article

References (12)

1. Hely MA, Morris JGL, Reid WGJ, O’Sullivan DJ, Willimason PM. Rail D, Broe GA, Margric S: The Sydney mullicentre study of Parkinson’s disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-910.
2. Monlastruc JL, Rascol O. Senard JM. Rascol A: A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: A five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
3. Nakanishi N, Iwata M, Goto I, Kanazawa I, Kowa H, Mannen T, Mizuno Y, Nishitani H, Ogawa N, Takahashi A, Tshiro K, Toghi H, Yanagisawa N: Nationwide collaborative study on the long term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol 1992;32(suppl):9-22.
4. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stem M, Shoulson I, Kurlan R, Grimes JD, Jankovic J, Hoehn M, Markham CH, Duvoisin R, Reinmuth O, Leonard HA, Ahlskog E, Feldman R, Hershey L, Yahr MD: A multicenter double-blind placebo controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease. Mov Disord 1994:9:40-47.
5. Gancher ST, Null JG, Woodward WR: Apo-morphinc infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance. Mov Disord 1995;10:37-43.
6. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stem GM: Subcutaneous apomorphinc in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170.
7. Langtry D, Clissold SP: Pergolide - a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990: 39:491-506.
8. Facca A, Sanchez-Ramos J: High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11:327-329.
9. Nutt JG, Carter JH, Woodward WR: Long-duration response to levodopa. Neurology 1995;45:1613-1616.
10. Komhuber J, Bormann J, Hubers M, Rusche K, Riederer P: Effects of the 1-amino-adaman-tanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human post mortem brain study. Eur J Pharmacol 1991;206:297-300.
11. Löschmann PA, Kunow M, Wachtel H: Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson’s disease. J Neural Transm 1992:38(suppl):55-64.
12. Papa SM, Chase TN: Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996:39: 574-578.